ConductScience.org, home

Paper4875331

Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci.

Okamoto H and 3 others. Jpn J Microbiol, 1967. Cited by 253 papers, by iCite.

Cite this record

ConductScience Library. Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci. Papers, record 4875331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4875331

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci.
PubMed
Journal
Jpn J Microbiol
PubMed
Year
1967
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
253
iCite
Revised in PubMed
2020-12-22
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Okamoto HH
2Shoin SS
3Koshimura SS
4Shimizu RR

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Neoplasms, ExperimentalMajor topic
StreptococcusMajor topic
StreptolysinsMajor topic
Animals
Culture Media
Culture Techniques
Neoplasm Transplantation
Penicillins
RNA
Ribonucleases
Streptococcal Infections

Source PubMed

Download CSV of topics

Cited by52

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 253 citations.

PMIDTitleJournalYearIn PapersSource
40726887Refractory Ranula Following Surgery for Tongue Cancer: A Case Report.Cureus2025https://conductscience.org/library/papers/40726887PubMed
40692748Enhanced efficacy of immune checkpoint inhibitors with OK-432 in malignant pleural mesothelioma: A case report.Mol Clin Oncol2025https://conductscience.org/library/papers/40692748PubMed
40400941Effect of OK-432 pleurodesis on long-term survival outcomes after pulmonary lobectomy for lung cancer patients: a retrospective case-control study.J Thorac Dis2025https://conductscience.org/library/papers/40400941PubMed
36548729Preliminary Exploration of a New Therapy for Interstitial Cystitis/Bladder Pain Syndrome: Botulinum Toxin A Combined with Sapylin.Toxins (Basel)2022https://conductscience.org/library/papers/36548729PubMed
34209347The Soluble Factor from Oral Cancer Cell Lines Inhibits Interferon-γ Production by OK-432 via the CD40/CD40 Ligand Pathway.Cancers (Basel)2021https://conductscience.org/library/papers/34209347PubMed
30486312OK-432 Administration Inhibits Murine Allergic Rhinitis at the Induction Phase, through the Macrophage Activation with TLR2 Signaling Pathway.Med Sci (Basel)2018https://conductscience.org/library/papers/30486312PubMed
29730580Toll-like receptors in immunity and inflammatory diseases: Past, present, and future.Int Immunopharmacol2018https://conductscience.org/library/papers/29730580PubMed
29666687Efficacy of OK-432 Therapy for the Incisionless Treatment of Head and Neck Cystic Masses: Case series.Sultan Qaboos Univ Med J2018https://conductscience.org/library/papers/29666687PubMed
27169846Experimental validation of talc pleurodesis for carcinomatous pleuritis in an animal model.Gen Thorac Cardiovasc Surg2016https://conductscience.org/library/papers/27169846PubMed
27141345Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy.Oncoimmunology2016https://conductscience.org/library/papers/27141345PubMed
26855819Dendritic cell-based vaccine for pancreatic cancer in Japan.World J Gastrointest Pharmacol Ther2016https://conductscience.org/library/papers/26855819PubMed
26101781Harnessing the Microbiome to Enhance Cancer Immunotherapy.J Immunol Res2015https://conductscience.org/library/papers/26101781PubMed
25804300The efficacy of adjuvant immunochemotherapy with OK-432 after curative resection of gastric cancer: an individual patient data meta-analysis of randomized controlled trials.Gastric Cancer2016https://conductscience.org/library/papers/25804300PubMed
25537519Classification of current anticancer immunotherapies.Oncotarget2014https://conductscience.org/library/papers/25537519PubMed
25083332Trial Watch: Toll-like receptor agonists in oncological indications.Oncoimmunology2014https://conductscience.org/library/papers/25083332PubMed
24083080Trial Watch: Toll-like receptor agonists for cancer therapy.Oncoimmunology2013https://conductscience.org/library/papers/24083080PubMed
23814492Immunochemoradiotherapy for patients with oral squamous cell carcinoma: augmentation of OK-432-induced helper T cell 1 response by 5-FU and X-ray irradiation.Neoplasia2013https://conductscience.org/library/papers/23814492PubMed
23526132Links between Toll-like receptor 4 and breast cancer.Oncoimmunology2013https://conductscience.org/library/papers/23526132PubMed
23359778The efficacy of the inhalation of an aerosolized Group A streptococcal preparation in the treatment of lung cancer.Chin J Cancer Res2012https://conductscience.org/library/papers/23359778PubMed
23300824TNF-α and tumor lysate promote the maturation of dendritic cells for immunotherapy for advanced malignant bone and soft tissue tumors.PLoS One2012https://conductscience.org/library/papers/23300824PubMed

See all 52 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/4875331

GET https://conductscience.org/api/papers/v1/4875331/cited_by?page=2